KLK3 and benign prostatic hyperplasia: Also, the first clinical trials revealed significant improvements in BPH symptoms and a significant decrease in prostate volume and PSA for at least 1 month after treatment, suggesting that lonidamine may be a therapeutic alternative for BPH (Ditonno et al. 2005).